0001847903-23-000161.txt : 20230922 0001847903-23-000161.hdr.sgml : 20230922 20230922164739 ACCESSION NUMBER: 0001847903-23-000161 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230920 FILED AS OF DATE: 20230922 DATE AS OF CHANGE: 20230922 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rotman Harris CENTRAL INDEX KEY: 0001981420 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40445 FILM NUMBER: 231272252 MAIL ADDRESS: STREET 1: C/O CENTESSA PHARMACEUTICALS PLC STREET 2: 3RD FL., 1 ASHLEY RD, ALTRINCHAM CITY: CHESHIRE STATE: X0 ZIP: WA14 2DT ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Centessa Pharmaceuticals plc CENTRAL INDEX KEY: 0001847903 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3RD FLOOR STREET 2: 1 ASHLEY ROAD CITY: ALTRINCHAM, CHESHIRE STATE: X0 ZIP: WA14 2DT BUSINESS PHONE: 44 7391 789784 MAIL ADDRESS: STREET 1: 3RD FLOOR STREET 2: 1 ASHLEY ROAD CITY: ALTRINCHAM, CHESHIRE STATE: X0 ZIP: WA14 2DT FORMER COMPANY: FORMER CONFORMED NAME: Centessa Pharmaceuticals Ltd DATE OF NAME CHANGE: 20210224 4 1 wk-form4_1695415648.xml FORM 4 X0508 4 2023-09-20 0 0001847903 Centessa Pharmaceuticals plc CNTA 0001981420 Rotman Harris C/O CENTESSA PHARMACEUTICALS PLC 3RD FL., 1 ASHLEY RD, ALTRINCHAM CHESHIRE X0 WA14 2DT UNITED KINGDOM 0 1 0 0 SVP Regulatory Affairs 1 Ordinary Shares 2023-09-20 4 M 0 31250 4.47 A 64750 D Ordinary Shares 2023-09-20 4 M 0 6234 3.85 A 70984 D Ordinary Shares 2023-09-20 4 S 0 37484 6.2877 D 33500 D Share Option (right to buy) 4.47 2023-09-20 4 M 0 31250 0 D 2032-08-01 Ordinary Shares 31250 93750 D Share Option (right to buy) 3.85 2023-09-20 4 M 0 6234 0 D 2033-02-01 Ordinary Shares 6234 43666 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 20, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.01 to $6.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. 25% of the shares subject to such option shall vest and become exercisable on August 1, 2023 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter. 6,234 of the shares vest and become exercisable on August 1, 2023 and 1/48th of the shares subject to such option shall vest and become exercisable in 42 monthly installments on the first day of each month thereafter. /s/ Gregory Weinhoff, attorney-in-fact 2023-09-22